Decision on optimal combinatorinal Therapies in IMIDS using Systems approaches
There is an urgent need to discover effective drug combinations that improve the limited efficacy of monotherapies in many common diseases. The present symposium will be a one-day online event where experts of both clinical and translational areas will share their experiences
CD80/86 axis blocking agent abatacept, selected among 130 immunomodulators to be tested in ACTIV-1 IM, a large randomized clinical trial on hospitalized COVID-19 patients. The candidate drug will be tested against anti-TNF therapy, CCR2/5 inhibitor and placebo in relation to
While vaccines are being developed to stop the COVID-19 pandemic, there is a major effort to prevent the high mortality associated with COVID-19 hyperinflammation. Researchers from the Vall Hebron Hospital Research Institute and IMIDomics have contributed to this endeavour by
The 20th January the eight European partners and one USA partner that constitute the DoCTIS Consortium held the kick-off meeting at the Vall Hebron University Hospital (VHIR).